Better results and fewer side effects with personalised DBS Therapy
sponsored by Boston Scientific
Author: Boston ScientificPublished: 31 May 2018
Prep: Cook: Serves:
Latest Deep Brain Stimulation devices offer a wide range of programming options to help personalise patient treatment. Looking to improve outcomes, Professor Jens Volkmann challenged the status quo and explored promising options
Pharmacological therapy for Parkinson’s disease is aimed at minimising the motor symptoms of the disease, but the side effects of medication can have a significant impact on quality of life. For many people with Parkinson’s – and their carers – motor symptoms are a major burden that can no longer be controlled by medication alone.
For those patients, Deep Brain Stimulation (DBS) therapy could be considered as a safe and effective surgical option. Until recently, DBS was only considered for people who had been living with Parkinson’s for several years. However, recent studies have shown that the sooner suitable subjects undergo DBS surgery, the more they can benefit. Professor Jens Volkmann, Professor and Chairman of the Department of Neurology at the University of Wurzburg, explains: “In younger patients, stimulation can be adjusted a lot easier because they don’t have to regain but rather maintain physical activity which makes a huge difference in the results.”
Motor symptoms such as tremor, rigidity, freezing, slowness of movement or involuntary movements can have a debilitating effect on daily life and social activities. DBS is one of the most effective therapies in reducing these symptoms, with some people able to reduce their medication by more than half.
Beneficial and safe results through personalised DBS therapy
To improve the outcomes of DBS therapy even further, ongoing studies are examining ways of avoiding potential side effects. Professor Volkmann says: “Our brains are all very individual and so is every course of Parkinson’s disease. As a result, every patient responds to DBS differently.”
Today, there are options to individualise and customise each person’s therapy so they can best benefit from it. Professor Volkmann adds: “With personalised stimulation, we can address the individual requirements of a patient’s brain so they can experience the beneficial results from it and also avoid side effects, such as speech disorder, at the same time.”
Shorter stimulation duration is key to fewer side effects
The latest device advancements on the market offer a very wide range of stimulation settings. Trying to identify the ideal setting options, together with a team, Professor Volkmann went against the status quo and found very interesting results. In particular, the team looked at adjusting the “pulse width”, which is one of the stimulation options.
Professor Volkmann says: “Within one second, approximately 130 electrical pulses are repeated to stimulate a specific area in the brain. With this electrical stimulation, we achieve a beneficial effect in a patient. The duration of each of these pulses is called the pulse width. Regulating the pulse width is comparable to dosing a medication. If the dosage of a drug is too low it will not be effective, if it is too high, the patient experiences side effects. With pulse width it is very similar.”
The study found that patients stimulated at a significantly lower pulse width experienced equally good results with even fewer side effects compared to those stimulated at the standard pulse width. He adds: “The newest devices enabled us to respond to the individual requirements of a patient’s brain in a way that was not possible before. This way, patients can receive an equally beneficial and even safer therapy.
“This is a huge step in the right direction. Researchers are continuously looking to improve DBS therapy and its results. I think it will not take long until we can develop a DBS therapy that is auto-adjusting itself based on the individual requirements of a patient’s brain. Technology is evolving incredibly fast and with research like this we are on the right track of finding ways to offer patients a DBS therapy with the best possible results and the fewest side effects at the same time.”
About Deep Brain Stimulation (DBS) therapy
The DBS procedure includes a modest medical device, which sends signals to the brain. The signals help control the motor functions that are affected by movement disorder symptoms such as tremor, slowness and rigidity. The physician will place one or two insulated wires called leads in the brain. The leads are then connected to the stimulator (similar to a pacemaker), which is typically placed under the skin in the chest. The device produces mild electrical impulses that stimulate a specific region of the brain. This may help regulate signalling in the brain, resulting in improvement of symptoms. This stimulation may help improve day-to-day experiences for people living with movement disorders such as Parkinson’s disease, dystonia, or essential tremor.
For comprehensive information on Deep Brain Stimulation and Parkinson’s, please visit the EPDA website or the Boston Scientific website.
This article is sponsored by Boston Scientific. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
A series of 12 videos to offer practical Parkinson’s advice
What would you do if you had one hour more of ‘on time’ each day?
1 day ago
Sir Billy Connolly: Parkinson’s disease is “like a strange animal”
Scottish comedian, actor and musician Sir Billy Connolly has recently discussed his experience of Parkinson’s disease while promoting his new autobiography, ‘Windswept & Interesting’. In an appearance on UK talk show, ‘The Graham Norton Show’, the comedian explained that he had lost the ability to write. He said: “It breaks my heart as I used to love writing letters to people.” Speaking to UK newspaper The Guardian, Connolly added that he thinks the condition is “like a strange animal. One that sits beside you and says, ‘How will you get on without this?’ – before it takes away something else.” Despite these adjustments, Connolly told Norton he has “good days and bad days” with the condition. “It’s creeping up on me and it never lets go,” he said. “I walk like a drunk man and have to have help. So, life is different, but it is good.” Lead image credit:…
New insights on immune cell process and Parkinson’s disease
Insoluble clumps of the protein alpha-synuclein, which can cause damage to brain cells, have been previously linked to Parkinson’s. Now, scientists in Germany, France and the US have uncovered new details on how brain cells respond to these clusters. The researchers discovered that the brain’s immune cells may be able to join together to break down the protein clumps. According to a press release, this was previously unknown. They also found that these neighbouring cells share mitochondria – structures that generate energy for chemical reactions – to help one another. In certain mutations associated with Parkinson’s, this process may be impaired. The researchers hope this insight could inform the development of new therapies. “We have opened the door to a field that will certainly engage researchers for many years to come,” said Professor Dr Michael Heneka, director of the Department of Neurodegenerative Diseases and Geriatric Psychiatry at the University Hospital…
Could analysing skin oil help diagnose Parkinson’s disease?
Parkinson’s disease patients tend to have high levels of oil, known as sebum, on their skin’s surface. Now, a study has suggested that analysing this substance may help when diagnosing the condition. The study revealed that sebum contains significant amounts of genetic material, specifically the molecule ribonucleic acid (RNA). Analysis of RNA contained in sebum – that is, skin surface lipids RNA, or SSL-RNA – could offer insights into a person’s health. Researchers in Japan examined SSL-RNA in men and women with and without Parkinson’s. The results suggested that the SSL-RNA profiles of those with Parkinson’s had “different characteristics” than those without. The researchers then tested whether examining these profiles with machine learning could reveal those who had Parkinson’s – and who didn’t. The team’s algorithm indicated a “relatively robust discriminatory ability,” supporting the further use of SSL-RNA as part of a future “non-invasive” method for diagnosis.